Abstracts tagged "ankylosing spondylitis (AS) and registries"

Abstract Number: 1541 • 2017 ACR/ARHP Annual Meeting
First Line Biological Treatment in Ankylosing Spondylitis, Prescription Rates, Baseline Demographics and Disease Activity. a Collaboration between Biological Registers in the Five Nordic Counties
Bente Glintborg¹, Ulf Lindström², Kalle Aaltonen³, Eirik K Kristianslund⁴, Björn Gudbjornsson⁵, Katerina Chatzidionysiou², Johan Askling⁶, Dan Nordström⁷, Merete Lund Hetland⁸, Daniela Di Giuseppe⁹, Lene Dreyer¹⁰, Tanja Schjødt Jørgensen¹¹, Lars Erik Kristensen¹⁰, Kari Eklund³, Gerdur Grondal¹², Sofia Ernestam², Jaana Joensuu³, Tore K Kvien¹³, Elisabeth Lie¹³, Karen M Fagerli¹³, Arni Jon Geirsson¹², Helgi Jonsson¹² and Lennart TH Jacobsson¹⁴, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²On behalf of the SRQ/ARTIS registry, Stockholm, Sweden, ³On behalf of the ROB-FIN registry, Helsinki, Finland, ⁴Dept. of Rheumatology, On behalf of the NOR-DMARD registry, Oslo, Norway, ⁵ICEBIO, Reykjavik, Iceland, Reykjavik, Iceland, ⁶Unit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁷ROB-FIN, Helsinki, Finland, Helsinki, Finland, ⁸The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark, ⁹Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ¹⁰On behalf of the DANBIO registry, Copenhagen, Denmark, ¹¹On behalf of the DANBIO registry, Copenhagen F, Denmark, ¹²On behalf of the ICEBIO registry, Reykjavik, Iceland, ¹³On behalf of the NOR-DMARD registry, Oslo, Norway, ¹⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Large-scale observational cohorts identified in national biological registries may be used to study effectiveness of biological disease modifying drugs (bDMARDs) in ankylosing spondylitis (AS).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].